Menu
Program
The program offers multiple perspectives on the HIV cure field, showcasing exciting recent research findings with potential for clinical translation.
The conference sessions will present the latest research and foster discussion on:
• The establishment of the HIV reservoir
• The adaptive and innate immune responses associated with HIV control
• The molecular characteristics of the viral reservoirs
• The development of new therapies
| MONDAY 11 SEPTEMBER 2023 | |
|---|---|
| 12.30-13.00 | Registration |
| 13.00-13.10 | Welcome and Introduction |
| 13.10-13.35 | KEYNOTE LECTURE |
| 13.10-13.35 | HIV care versus cure in Europe anno 2023: mapping the impact of the Ukraine war Milosz Parczewski, Pomeranian Medical University, Szczecin, Poland |
| 13.35-14.00 | HIV RESERVOIR ESTABLISHMENT |
| 13.35-14.00 | Within-host HIV reservoir dynamics Zabrina Brumme, Simon Fraser University, Burnaby, Canada |
| 14.00-14.25 | Inflammatory profile and viral reservoir after treatment initiation during acute HIV-1 infection Jozefien De Clercq, HIV Cure Research Center, Ghent University, Ghent, Belgium |
| 14.25-14.45 | Abstract Presentations |
| 14.45-15.05 | Break |
| 15.05-16.15 | HIV PERSISTENCE |
| 15.05-15.30 | Proviruses in self-reactive CD4+ T-cells are a common source of residual HIV viremia Francesco Simonetti, Johns Hopkins University, Maryland, United States |
| 15.30-15.55 | Defining molecular pathways triggered by IL-10 and TGFb that drive HIV integration and persistence in Tfh cells in lymph nodes Susan Ribeiro, Emory University, Atlanta, United States |
| 15.55-16.15 | Abstract Presentations |
| 16.15-16.35 | Break |
| 16.35-18.10 | THE HIV RESERVOIR PHENOTYPE |
| 16.35-17.00 | T-TRACE and HIV-seq enable single-cell multi-omics analysis of HIV reservoir cells Nadia Roan, Gladstone Institutes and University of California San Francisco (UCSF), California, United States |
| 17.00-17.25 | Immunological consequences of spontaneous HIV reservoir activity during suppressive ART Daniel Kaufmann, University of Lausanne, Lausanne, Switzerland |
| 17.25-17.50 | HIV silencing and cell survival signatures in infected T-cell reservoirs Eli Boritz, NIAID Vaccine Research Center, Bethesda, United States |
| 17.50-18.10 | Abstract Presentations |
| 18.10-19.30 | NETWORK RECEPTION |
| TUESDAY 12 SEPTEMBER 2023 | |
|---|---|
| 08.30-09.00 | Registration |
| 09.00-09.40 | KEYNOTE LECTURE |
| 09.00-09.40 | Multi-omics dissection of mechanisms of HIV persistence and immune dysfunction Rafick-Pierre Sekaly, Emory University, Atlanta, United States |
| 09.40-10.50 | CHARACTERISTICS OF THE IMMUNE SYSTEM AND THE HIV-1 RESERVOIR IN THE 2000HIV COHORT |
| 09.40-10.05 | Virological aspects of fast and slow progressors in the 2000HIV cohort Linos Vandekerckhove, Ghent University, Belgium |
| 10.05-10.30 | Monocytes of HIV-1 elite controllers and relatives show enhanced trained immunity Mihai Netea, Radboud University Medical Center, The Netherlands |
| 10.30-10.50 | Abstract Presentations |
| 10.50-11.30 | Poster Session + Break |
| 11.30-12.40 | HIV-1 POST TREATMENT CONTROL |
| 11.30-11.55 | Single Infusion of STEM like CCR5-modified CD4 T cells provide long-term HIV control Ashish Sharma, Emory University, Atlanta, United States |
| 11.55-12.20 | HIV post-treatment controllers have distinct immunological and virological features Jonathan Li, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States |
| 12.20-12.40 | Abstract Presentations |
| 12.40-14.00 | Lunch |
| 14.00-15.00 | SATELLITE SYMPOSIUM |
| 14.00-15.00 | Innovating towards a Cure: Gilead’s Immunotherapy Strategy Elena Vendrame, Gilead Sciences, California, United States |
| 15.00-16.25 | DESIGNING THERAPEUTIC OPTIONS FOR HIV CONTROL |
| 15.00-15.25 | Soluble T cell receptor bispecific biologics for HIV Lucy Dorrell, Immunocore and University of Oxford, United Kingdom |
| 15.25-15.50 | Genetic editing of B cells aiming for an HIV cure Anne Galy, ART-TG Inserm, Corbeil-Essonnes, France |
| 15.50-16.10 | Abstract Presentations |
| 16.10-16.30 | Break |
| 16.30-17.45 | CORRELATES OF HIV CONTROL AND PERSISTENCE |
| 16.30-16.55 | Combination Immunotherapy and Post-Interventional Control Steven Deeks, UCSF San Francisco, United States |
| 16.55-17.20 | HIV control in antibody and combination therapy cure studies Martin Tolstrup, Aarhus University, Denmark |
| 17.20-17.40 | Abstract Presentations |
| 17.40-17.45 | Closing remarks |
WERELDWIJD LEVEN 37 MILJOEN MENSEN MET HIV. STEUN HET FONDS HIV ONTRAFELEN en Help hen.
| TUESDAY 12 SEPTEMBER 2023 | |
|---|---|
| 08.30-09.00 | Registration |
| 09.00-09.40 | KEYNOTE LECTURE |
| 09.00-09.40 | Multi-omics dissection of mechanisms of HIV persistence and immune dysfunction Rafick-Pierre Sekaly, Emory University, Atlanta, United States |
| 09.40-10.50 | CHARACTERISTICS OF THE IMMUNE SYSTEM AND THE HIV-1 RESERVOIR IN THE 2000HIV COHORT |
| 09.40-10.05 | Virological aspects of fast and slow progressors in the 2000HIV cohort Linos Vandekerckhove, Ghent University, Belgium |
| 10.05-10.30 | Monocytes of HIV-1 elite controllers and relatives show enhanced trained immunity Mihai Netea, Radboud University Medical Center, The Netherlands |
| 10.30-10.50 | Abstract Presentations |
| 10.50-11.30 | Poster Session + Break |
| 11.30-12.40 | HIV-1 POST TREATMENT CONTROL |
| 11.30-11.55 | Single Infusion of STEM like CCR5-modified CD4 T cells provide long-term HIV control Ashish Sharma, Emory University, Atlanta, United States |
| 11.55-12.20 | HIV post-treatment controllers have distinct immunological and virological features Jonathan Li, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States |
| 12.20-12.40 | Abstract Presentations |
| 12.40-14.00 | Lunch |
| 14.00-15.00 | SATELLITE SYMPOSIUM |
| 14.00-15.00 | Innovating towards a Cure: Gilead’s Immunotherapy Strategy Elena Vendrame, Gilead Sciences, California, United States |
| 15.00-16.25 | DESIGNING THERAPEUTIC OPTIONS FOR HIV CONTROL |
| 15.00-15.25 | Soluble T cell receptor bispecific biologics for HIV Lucy Dorrell, Immunocore and University of Oxford, United Kingdom |
| 15.25-15.50 | Genetic editing of B cells aiming for an HIV cure Anne Galy, ART-TG Inserm, Corbeil-Essonnes, France |
| 15.50-16.10 | Abstract Presentations |
| 16.10-16.30 | Break |
| 16.30-17.45 | CORRELATES OF HIV CONTROL AND PERSISTENCE |
| 16.30-16.55 | Combination Immunotherapy and Post-Interventional Control Steven Deeks, UCSF San Francisco, United States |
| 16.55-17.20 | HIV control in antibody and combination therapy cure studies Martin Tolstrup, Aarhus University, Denmark |
| 17.20-17.40 | Abstract Presentations |
| 17.40-17.45 | Closing remarks |
Doe een online gift
-
Of via overschrijving:
Universiteitsfonds UGent - IBAN BE26 3900 9658 0329
- BIC BBRUBEBB
- Met duidelijke vermelding: HIVOntrafelen
- Giften vanaf 40 euro per jaar zijn 45% fiscaal aftrekbaar. Meer informatie: www.ugent.be/iksteunmee